FDLI book maps out multi-country pharmacovigilance

5 May 2009

As recent events clearly indicate, the need to keep a close eye on pharmaceutical safety does not end with government approval to market  the drug, says the USA-based Food and Drug Law Institute.

In March 2008, shipments of the blood thinner heparin made in China were  discovered to be contaminated with excess sulfates often used to treat  arthritis. The contaminated heparin caused dozens of deaths and hundreds  of injuries. In February this year, the Food and Drug Administration  accused Indian generic drugmaker Ranbaxy of falsifying data used to  obtain regulatory approval for US distribution (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight